Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $39
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $40
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Cuts Target Price to $43
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
Baird Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $92
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $61
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $39 to $85
Apellis Pharmaceuticals Is Maintained at Neutral by Mizuho
Apellis European Rejection for Vision Treatment Dents Revenue Growth, Stock Performance, Wedbush Says
What's Going With Apellis Pharmaceuticals Stock Friday?
Wedbush Cuts Price Target on Apellis Pharmaceuticals to $35 From $41, Maintains Neutral Rating; Shares Fall
Buy Rating on Apellis Pharmaceuticals Anchored in Syfovre's Market Share Potential Despite EU Setback
Sector Update: Health Care Stocks Rise Premarket Friday
Express News | Apellis Pharmaceuticals Inc : Piper Sandler Cuts Target Price to $40 From $46
Sector Update: Health Care
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $39
Express News | Apellis Pharmaceuticals Shares Down 5.8% Premarket After EU Panel Confirms Negative Opinion for Eye Disease Drug
Apellis: CHMP Once Again Recommends Against Syfovre